Single-nucleotide Polymorphisms in the p53 Signaling Pathway

被引:80
作者
Grochola, Lukasz F. [1 ]
Zeron-Medina, Jorge [1 ]
Meriaux, Sophie [1 ]
Bond, Gareth L. [1 ]
机构
[1] Univ Oxford, Ludwig Inst Canc Res, Oxford OX3 7DQ, England
来源
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY | 2010年 / 2卷 / 05期
关键词
SQUAMOUS-CELL CARCINOMA; P73; G4C14-TO-A4T14; POLYMORPHISM; CHRONIC LYMPHOCYTIC-LEUKEMIA; ATM-DEPENDENT PHOSPHORYLATION; CONTRALATERAL BREAST-CANCER; ACCELERATES TUMOR-FORMATION; MDM2 PROMOTER POLYMORPHISM; LI-FRAUMENI-SYNDROME; LUNG-CANCER; COLORECTAL-CANCER;
D O I
10.1101/cshperspect.a001032
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The p53 tumor suppressor pathway is central both in reducing cancer frequency in vertebrates and in mediating the response of commonly used cancer therapies. This article aims to summarize and discuss a large body of evidence suggesting that the p53 pathway harbors functional inherited single-nucleotide polymorphisms (SNPs) that affect p53 signaling in cells, resulting in differences in cancer risk and clinical outcome in humans. The insights gained through these studies into how the functional p53 pathway SNPs could help in the tailoring of cancer therapies to the individual are discussed. Moreover, recent work is discussed that suggests that many more functional p53 pathway SNPs are yet to be fully characterized and that a thorough analysis of the functional human genetics of this important tumor suppressor pathway is required.
引用
收藏
页数:18
相关论文
共 140 条
[51]   Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers:: an update [J].
Gronwald, J ;
Tung, N ;
Foulkes, WD ;
Offit, K ;
Gershoni, R ;
Daly, M ;
Kim-Sing, C ;
Olsson, H ;
Ainsworth, P ;
Eisen, A ;
Saal, H ;
Friedman, E ;
Olopade, O ;
Osborne, M ;
Weitzel, J ;
Lynch, H ;
Ghadirian, P ;
Lubinski, J ;
Sun, P ;
Narod, SA .
INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (09) :2281-2284
[52]   MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia [J].
Gryshchenko, Irina ;
Hofbauer, Sebastian ;
Stoecher, Markus ;
Daniel, Peter T. ;
Steurer, Michael ;
Gaiger, Alexander ;
Eigenberger, Karin ;
Greil, Richard ;
Tinhofer, Inge .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (14) :2252-2257
[53]   WAF1 genotype and endometrial cancer susceptibility [J].
Hachiya, T ;
Kuriaki, Y ;
Ueoka, Y ;
Nishida, J ;
Kato, K ;
Wake, N .
GYNECOLOGIC ONCOLOGY, 1999, 72 (02) :187-192
[54]  
Harima Y, 2001, INT J MOL MED, V7, P261
[55]   MOLECULAR-BASIS FOR HETEROGENEITY OF THE HUMAN P53-PROTEIN [J].
HARRIS, N ;
BRILL, E ;
SHOHAT, O ;
PROKOCIMER, M ;
WOLF, D ;
ARAI, N ;
ROTTER, V .
MOLECULAR AND CELLULAR BIOLOGY, 1986, 6 (12) :4650-4656
[56]   Importance of p53 for cancer onset and therapy [J].
Haupt, Sue ;
Haupt, Ygal .
ANTI-CANCER DRUGS, 2006, 17 (07) :725-732
[57]   Mdm2 promotes the rapid degradation of p53 [J].
Haupt, Y ;
Maya, R ;
Kazaz, A ;
Oren, M .
NATURE, 1997, 387 (6630) :296-299
[58]   The biochemistry of apoptosis [J].
Hengartner, MO .
NATURE, 2000, 407 (6805) :770-776
[59]   MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma [J].
Hirata, Hiroshi ;
Hinoda, Yuji ;
Kikuno, Nobuyuki ;
Kawamoto, Ken ;
Suehiro, Yutaka ;
Tanaka, Yuichiro ;
Dahiya, Rajvir .
CLINICAL CANCER RESEARCH, 2007, 13 (14) :4123-4129
[60]   The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma [J].
Hong, Y ;
Miao, XP ;
Zhang, XM ;
Ding, F ;
Luo, AP ;
Guo, YL ;
Tan, W ;
Liu, ZH ;
Lin, DX .
CANCER RESEARCH, 2005, 65 (20) :9582-9587